Measles Antibody IgG Test

Getting two MMR (measles, mumps, rubella) shots as a child does not guarantee you are still protected today. Studies of healthcare workers who received both recommended doses show that roughly 10 to 20 percent no longer have measles antibody levels high enough to be considered protective when tested a decade later. If you were born after widespread vaccination replaced natural measles infection, your immunity may be weaker and shorter-lived than you assume.

Measles IgG (immunoglobulin G, the long-lasting antibody class) is the standard way to answer a simple question: are you still immune? Your routine blood panel does not include it. A normal complete blood count and metabolic panel tell you nothing about whether your body could fight off measles if you were exposed tomorrow. This test fills that gap.

What This Test Measures

Measles IgG is a specific type of antibody your immune system builds against measles virus proteins. After you are vaccinated or recover from a measles infection, specialized immune cells called plasma cells settle into your bone marrow and lymph tissue, where they can continue producing these antibodies for years or even decades. The test measures how much of this antibody is circulating in your blood right now.

The higher your measles IgG level, the more confident you can be that your body would neutralize the virus before it could make you sick. Below a certain threshold, you are considered susceptible, meaning the virus could gain a foothold and cause disease. The widely used protective threshold is around 120 to 200 mIU/mL depending on the lab assay, calibrated against the gold-standard plaque reduction neutralization test (a lab method that directly measures whether your antibodies can block the virus) endorsed by the World Health Organization.

Natural Infection vs. Vaccination

Not all measles immunity is created equal. People who caught measles before the vaccine era tend to carry very high, durable antibody levels, often above 900 to 1,000 mIU/mL, with blood tests still showing protective antibodies in over 95 percent of cases even decades later. Vaccination produces effective immunity in most people, but the antibody levels it generates are typically lower and fade more over time.

In large cohorts of twice-vaccinated young adults and healthcare workers, about 10 to 20 percent test below protective IgG thresholds 10 or more years after their last dose. This does not necessarily mean they are completely unprotected. Many of these individuals still carry immune memory cells that can rapidly produce antibodies if exposed to the virus. But the gap between "probably still protected by memory" and "definitely protected by circulating antibody" is exactly the gap this test helps you see.

Who Has Immunity Gaps

Age and birth cohort are the strongest predictors of where your antibody level likely falls. If you were born before widespread vaccination and had natural measles, your IgG is almost certainly high. If you were vaccinated but never exposed to circulating virus (increasingly common as measles cases declined), your levels may have quietly drifted below the protective line.

Large-scale antibody surveys across Europe and Asia consistently show that adults born after vaccine programs began have measurable immunity gaps. In Austrian cohorts, 13 to 20 percent of people born after 1990 tested negative for protective antibodies. A meta-analysis of European healthcare workers found 13.3 percent lacked protective measles IgG. These gaps are what allow outbreaks to occur even in countries with high overall vaccination rates.

• Adults born after 1970 in high-income countries: most likely vaccinated rather than naturally infected, and therefore at higher risk of waned immunity
• Immunocompromised individuals: about 25 percent of adults with cancer and 20 percent of children on active treatment lack measles IgG despite prior vaccination
• People living with HIV: substantially lower measles antibody levels compared to HIV-negative peers, even with similar vaccine coverage
• Infants under 12 months: maternal antibodies transferred during pregnancy drop below protective levels by 3 to 6 months, leaving a vulnerability window before the first scheduled vaccine dose

Why Measles Still Matters

Measles is not a mild childhood illness. It suppresses the immune system for weeks to months after infection, erasing memory your body has built against other pathogens. In unvaccinated populations, it carries a case fatality rate that makes it one of the most dangerous vaccine-preventable diseases. Even in well-resourced countries, outbreaks continue to occur when immunity gaps align with imported cases.

For adults, the consequences of unrecognized susceptibility extend beyond personal risk. If you work in healthcare, travel internationally, or spend time around infants too young to be vaccinated, knowing your actual antibody level lets you act before exposure rather than after.

Reference Ranges

Measles IgG results are reported differently depending on the lab and assay platform. The most common commercial assays (such as Euroimmun, Diasorin LIAISON, and Serion) calibrate their results to the WHO Third International Standard and report values in mIU/mL or IU/L. A single universal protective threshold does not exist, but two benchmarks appear consistently across studies.

Some assay manufacturers use slightly different cutoffs that vary by kit version. For example, certain Euroimmun assays define negative as below 200 IU/L, equivocal as 200 to 275 IU/L, and positive as 275 IU/L or above, while other versions use lower thresholds. The Diasorin LIAISON uses a positive cutoff of about 16.5 AU/mL (roughly 175 mIU/mL). Always compare your results to the reference range printed on your specific lab report, and compare serial results from the same lab for the most reliable trend.

When Results Can Be Misleading

The biggest source of misinterpretation is equating a negative IgG result with zero protection. Many twice-vaccinated individuals who test below the protective IgG threshold still carry immune memory cells capable of mounting a rapid antibody response upon re-exposure. Studies show these people often produce a strong "booster" response when given an additional MMR dose, confirming that their immune system remembers measles even though circulating antibody has dipped. A single low reading does not mean you were never vaccinated or that vaccination failed entirely.

Assay differences are another common trap. Different commercial kits can classify the same sample as negative, equivocal, or positive depending on their specific cutoff values. Neutralization assays, which directly test whether your antibodies can block the virus in a lab dish (the gold standard), sometimes show protective capacity in samples that standard commercial antibody tests call equivocal or negative. If a borderline result is driving a decision about revaccination or job clearance, requesting a neutralization-based confirmation can resolve the ambiguity.

• Immunoglobulin replacement therapy (IVIG or subcutaneous IG): If you receive regular immunoglobulin infusions for an immune deficiency, your measles IgG will reflect the antibodies in the product, not your own immune memory. The lowest level between doses (called the trough level) is typically around 1,300 mIU/mL on standard dosing. This result means you are protected passively, but it does not tell you whether your own plasma cells would produce antibody if the infusions stopped.
• B-cell depleting therapies (rituximab, ocrelizumab): B cells are the immune cells that mature into antibody-producing plasma cells. These medications, used for autoimmune conditions and certain cancers, suppress B cells and can lower overall IgG levels. A negative measles IgG in this context may reflect drug effect rather than true absence of prior immunity.
• Recent MMR vaccination: IgG rises over 2 to 6 weeks after vaccination. Testing too soon after a dose may give a falsely low reading that does not reflect the immune response still building.